BMSON Header

보건의료전문가가 아닌 경우, 한국BMS Official Site 을 방문해 주세요.

Log In Log Out My Profile Contact Us

제품
- Hematology
- Oncology
- Immunology
- Cardiology
- Virology
INREBIC^®(fedratinib)

ONUREG^®(azacitidine)

REBLOZYL^®(luspatercept-aamt)

REVLIMID^®(lenalidomide)/POMALYST^®(pomalidomide)

SPRYCEL^®(dasatinib)

™(thalidomide)

VIDAZA^®(azacitidine)

OPDIVO^®(nivolumab) / YERVOY^®(ipilimumab)

ABRAXANE^®(paclitaxel protein-bound particles for injectable suspension) (albumin-bound)

AUGTYRO^®(repotrectinib)

ZEPOSIA^®(ozanimod)

ORENCIA^®(abatacept)

SOTYKTU^™(sotyktu)

ELIQUIS^®(apixaban)

CAMZYOS^®(mavacamten)

BARACLUDE^®(entecavir)
웨비나 다시보기 & VOD
- 웨비나 다시보기
- VOD 콘텐츠
BMS 소식
- 뉴스 & 공지사항
- 사회공헌활동
BMS 직원방문 및 연락 요청
의학정보요청 및 이상사례보고
파이프라인

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

foot note heading

Quick Links

제품
웨비나 & VOD
BMS 소식
BMS 직원방문 및 연락요청
의학정보요청 및 이상사례보고

쿠키 설정

The information provided on this website is intended for Korea-licensed healthcare professionals only and is provided as general information. It is not intended as legal, medical or other professional advice.

© 2026 BMS Pharmaceutical Korea Limited.
ALL RIGHTS RESERVED.

466-KR-2600002 Feb 2026